A detailed history of Slate Path Capital LP transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Slate Path Capital LP holds 2,402,455 shares of CUE stock, worth $2.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,402,455
Previous 2,402,455 -0.0%
Holding current value
$2.4 Million
Previous $2.98 Million 38.74%
% of portfolio
0.03%
Previous 0.06%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$2.39 - $3.95 $2.2 Million - $3.63 Million
918,836 Added 61.93%
2,402,455 $6.85 Million
Q3 2020

Nov 16, 2020

BUY
$15.05 - $23.54 $9.22 Million - $14.4 Million
612,925 Added 70.39%
1,483,619 $22.3 Million
Q1 2020

May 15, 2020

SELL
$9.85 - $22.27 $190,164 - $429,944
-19,306 Reduced 2.17%
870,694 $12.4 Million
Q3 2019

Nov 14, 2019

BUY
$6.78 - $9.28 $6.03 Million - $8.26 Million
890,000 New
890,000 $7.5 Million

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $35.4M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Slate Path Capital LP Portfolio

Follow Slate Path Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Slate Path Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Slate Path Capital LP with notifications on news.